

I hereby certify that this correspondence is being delivered by Hand
Delivery to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

PATENT
Attorney Docket No.: 018781-002710US
Client Reference No.: T99-008-1

On _____

TOWNSEND and TOWNSEND and CREW LLP

By: _____

RECEIVED

DEC 02 2004

OFFICE OF PETITIONS

#29

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Lawrence R. McGee
Jonathan B. Houze

Application No.: 09/606,433

Filed: June 28, 2000

For: COMPOUNDS FOR THE
MODULATION OF PPAR γ ACTIVITY

Examiner: Seaman, J.

Art Unit: 1625

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT UNDER 37
CFR §1.97 and §1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on the attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the references are enclosed herewith. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.


As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement.

However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,


Frank J. Mycroft
Reg. No. 46,946

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 925-472-5000
Fax: 925-472-8895
FJM:jvl
60368070 v1

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known		
			Application Number	09/606,433	
			Filing Date	June 28, 2000	
			First Named Inventor	McGee, Lawrence R.	
			Art Unit	1625	
Examiner Name	Seaman, J.				
Sheet	1	of	1	Attorney Docket Number	018781-002710US

U.S. PATENT DOCUMENTS+					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (if known)			
	1.	5,204,354 A	04-20-1993	Chakravarty et al.	
	2.	6,262,112 B1	07-17-2001	Mittendorf et al.	
	3.	6,348,474 B1	02-19-2002	Kayakiri et al.	
	4.	6,469,054 B1	10-22-2002	Mittendorf et al.	
	5.	6,545,050 B1	04-08-2003	Mittendorf et al.	
	6.	6,653,309 B1	11-25-2003	Saunders et al.	
	7.	6,586,475 B1	07-01-2003	Kato et al.	
	8.	2004-048891 A1	03-11-2004	Kato et al.	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	9.	JP	9-255656	A	09-30-1997	Hidaka, Hiroyoshi et al.		<input checked="" type="checkbox"/>
	10.	WO	98/27081	A1	06-25-1998	Smithkline Beecham		<input type="checkbox"/>
	11.	WO	96/09294	A1	03-28-1996	Wellcome Foundation		<input type="checkbox"/>
	12.	WO	98/02437	A1	01-22-1998	Glaxo Group Ltd.		<input type="checkbox"/>
	13.	WO	98/50029	A1	11-12-1998	U of Pittsburgh		<input type="checkbox"/>
	14.	WO	98/50030	A1	11-12-1998	U of Pittsburgh		<input type="checkbox"/>
	15.	WO	99/55663	A1	11-04-1999	Vertex Pharmaceuticals		<input type="checkbox"/>
	16.	WO	00/12073	A1	03-09-2000	Smithkline Beecham		<input type="checkbox"/>
	17.	WO	00/12623	A2	03-09-2000	Smithkline Beecham		<input type="checkbox"/>
	18.	WO	00/17202	A1	03-30-2000	BASF		<input type="checkbox"/>
								<input type="checkbox"/>

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.